Cargando…

Insulin resistance contributes to racial disparities in breast cancer prognosis in US women

BACKGROUND: Racial disparities in breast cancer survival between Black and White women persist across all stages of breast cancer. The metabolic syndrome (MetS) of insulin resistance disproportionately affects more Black than White women. It has not been discerned if insulin resistance mediates the...

Descripción completa

Detalles Bibliográficos
Autores principales: Gallagher, Emily J., Fei, Kezhen, Feldman, Sheldon M., Port, Elisa, Friedman, Neil B., Boolbol, Susan K., Killelea, Brigid, Pilewskie, Melissa, Choi, Lydia, King, Tari, Nayak, Anupma, Franco, Rebeca, Cruz, Daliz, Antoniou, Irini M., LeRoith, Derek, Bickell, Nina A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216707/
https://www.ncbi.nlm.nih.gov/pubmed/32393319
http://dx.doi.org/10.1186/s13058-020-01281-y
_version_ 1783532467414630400
author Gallagher, Emily J.
Fei, Kezhen
Feldman, Sheldon M.
Port, Elisa
Friedman, Neil B.
Boolbol, Susan K.
Killelea, Brigid
Pilewskie, Melissa
Choi, Lydia
King, Tari
Nayak, Anupma
Franco, Rebeca
Cruz, Daliz
Antoniou, Irini M.
LeRoith, Derek
Bickell, Nina A.
author_facet Gallagher, Emily J.
Fei, Kezhen
Feldman, Sheldon M.
Port, Elisa
Friedman, Neil B.
Boolbol, Susan K.
Killelea, Brigid
Pilewskie, Melissa
Choi, Lydia
King, Tari
Nayak, Anupma
Franco, Rebeca
Cruz, Daliz
Antoniou, Irini M.
LeRoith, Derek
Bickell, Nina A.
author_sort Gallagher, Emily J.
collection PubMed
description BACKGROUND: Racial disparities in breast cancer survival between Black and White women persist across all stages of breast cancer. The metabolic syndrome (MetS) of insulin resistance disproportionately affects more Black than White women. It has not been discerned if insulin resistance mediates the link between race and poor prognosis in breast cancer. We aimed to determine whether insulin resistance mediates in part the association between race and breast cancer prognosis, and if insulin receptor (IR) and insulin-like growth factor receptor (IGF-1R) expression differs between tumors from Black and White women. METHODS: We conducted a cross-sectional, multi-center study across ten hospitals. Self-identified Black women and White women with newly diagnosed invasive breast cancer were recruited. The primary outcome was to determine if insulin resistance, which was calculated using the homeostatic model assessment of insulin resistance (HOMA-IR), mediated the effect of race on prognosis using the multivariate linear mediation model. Demographic data, anthropometric measurements, and fasting blood were collected. Poor prognosis was defined as a Nottingham Prognostic Index (NPI) > 4.4. Breast cancer pathology specimens were evaluated for IR and IGF-1R expression by immunohistochemistry (IHC). RESULTS: Five hundred fifteen women were recruited (83% White, 17% Black). The MetS was more prevalent in Black women than in White women (40% vs 20%, p < 0.0001). HOMA-IR was higher in Black women than in White women (1.9 ± 1.2 vs 1.3 ± 1.4, p = 0.0005). Poor breast cancer prognosis was more prevalent in Black women than in White women (28% vs 15%. p = 0.004). HOMA-IR was positively associated with NPI score (r = 0.1, p = 0.02). The mediation model, adjusted for age, revealed that HOMA-IR significantly mediated the association between Black race and poor prognosis (β = 0.04, 95% CI 0.005–0.009, p = 0.002). IR expression was higher in tumors from Black women than in those from White women (79% vs 52%, p = 0.004), and greater IR/IGF-1R ratio was also associated with higher NPI score (IR/IGF-1R >  1: 4.2 ± 0.8 vs IR/IGF-1R = 1: 3.9 ± 0.8 vs IR/IGF-1R < 1: 3.5 ± 1.0, p < 0.0001). CONCLUSIONS: In this multi-center, cross-sectional study of US women with newly diagnosed invasive breast cancer, insulin resistance is one factor mediating part of the association between race and poor prognosis in breast cancer.
format Online
Article
Text
id pubmed-7216707
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72167072020-05-18 Insulin resistance contributes to racial disparities in breast cancer prognosis in US women Gallagher, Emily J. Fei, Kezhen Feldman, Sheldon M. Port, Elisa Friedman, Neil B. Boolbol, Susan K. Killelea, Brigid Pilewskie, Melissa Choi, Lydia King, Tari Nayak, Anupma Franco, Rebeca Cruz, Daliz Antoniou, Irini M. LeRoith, Derek Bickell, Nina A. Breast Cancer Res Research Article BACKGROUND: Racial disparities in breast cancer survival between Black and White women persist across all stages of breast cancer. The metabolic syndrome (MetS) of insulin resistance disproportionately affects more Black than White women. It has not been discerned if insulin resistance mediates the link between race and poor prognosis in breast cancer. We aimed to determine whether insulin resistance mediates in part the association between race and breast cancer prognosis, and if insulin receptor (IR) and insulin-like growth factor receptor (IGF-1R) expression differs between tumors from Black and White women. METHODS: We conducted a cross-sectional, multi-center study across ten hospitals. Self-identified Black women and White women with newly diagnosed invasive breast cancer were recruited. The primary outcome was to determine if insulin resistance, which was calculated using the homeostatic model assessment of insulin resistance (HOMA-IR), mediated the effect of race on prognosis using the multivariate linear mediation model. Demographic data, anthropometric measurements, and fasting blood were collected. Poor prognosis was defined as a Nottingham Prognostic Index (NPI) > 4.4. Breast cancer pathology specimens were evaluated for IR and IGF-1R expression by immunohistochemistry (IHC). RESULTS: Five hundred fifteen women were recruited (83% White, 17% Black). The MetS was more prevalent in Black women than in White women (40% vs 20%, p < 0.0001). HOMA-IR was higher in Black women than in White women (1.9 ± 1.2 vs 1.3 ± 1.4, p = 0.0005). Poor breast cancer prognosis was more prevalent in Black women than in White women (28% vs 15%. p = 0.004). HOMA-IR was positively associated with NPI score (r = 0.1, p = 0.02). The mediation model, adjusted for age, revealed that HOMA-IR significantly mediated the association between Black race and poor prognosis (β = 0.04, 95% CI 0.005–0.009, p = 0.002). IR expression was higher in tumors from Black women than in those from White women (79% vs 52%, p = 0.004), and greater IR/IGF-1R ratio was also associated with higher NPI score (IR/IGF-1R >  1: 4.2 ± 0.8 vs IR/IGF-1R = 1: 3.9 ± 0.8 vs IR/IGF-1R < 1: 3.5 ± 1.0, p < 0.0001). CONCLUSIONS: In this multi-center, cross-sectional study of US women with newly diagnosed invasive breast cancer, insulin resistance is one factor mediating part of the association between race and poor prognosis in breast cancer. BioMed Central 2020-05-12 2020 /pmc/articles/PMC7216707/ /pubmed/32393319 http://dx.doi.org/10.1186/s13058-020-01281-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Gallagher, Emily J.
Fei, Kezhen
Feldman, Sheldon M.
Port, Elisa
Friedman, Neil B.
Boolbol, Susan K.
Killelea, Brigid
Pilewskie, Melissa
Choi, Lydia
King, Tari
Nayak, Anupma
Franco, Rebeca
Cruz, Daliz
Antoniou, Irini M.
LeRoith, Derek
Bickell, Nina A.
Insulin resistance contributes to racial disparities in breast cancer prognosis in US women
title Insulin resistance contributes to racial disparities in breast cancer prognosis in US women
title_full Insulin resistance contributes to racial disparities in breast cancer prognosis in US women
title_fullStr Insulin resistance contributes to racial disparities in breast cancer prognosis in US women
title_full_unstemmed Insulin resistance contributes to racial disparities in breast cancer prognosis in US women
title_short Insulin resistance contributes to racial disparities in breast cancer prognosis in US women
title_sort insulin resistance contributes to racial disparities in breast cancer prognosis in us women
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216707/
https://www.ncbi.nlm.nih.gov/pubmed/32393319
http://dx.doi.org/10.1186/s13058-020-01281-y
work_keys_str_mv AT gallagheremilyj insulinresistancecontributestoracialdisparitiesinbreastcancerprognosisinuswomen
AT feikezhen insulinresistancecontributestoracialdisparitiesinbreastcancerprognosisinuswomen
AT feldmansheldonm insulinresistancecontributestoracialdisparitiesinbreastcancerprognosisinuswomen
AT portelisa insulinresistancecontributestoracialdisparitiesinbreastcancerprognosisinuswomen
AT friedmanneilb insulinresistancecontributestoracialdisparitiesinbreastcancerprognosisinuswomen
AT boolbolsusank insulinresistancecontributestoracialdisparitiesinbreastcancerprognosisinuswomen
AT killeleabrigid insulinresistancecontributestoracialdisparitiesinbreastcancerprognosisinuswomen
AT pilewskiemelissa insulinresistancecontributestoracialdisparitiesinbreastcancerprognosisinuswomen
AT choilydia insulinresistancecontributestoracialdisparitiesinbreastcancerprognosisinuswomen
AT kingtari insulinresistancecontributestoracialdisparitiesinbreastcancerprognosisinuswomen
AT nayakanupma insulinresistancecontributestoracialdisparitiesinbreastcancerprognosisinuswomen
AT francorebeca insulinresistancecontributestoracialdisparitiesinbreastcancerprognosisinuswomen
AT cruzdaliz insulinresistancecontributestoracialdisparitiesinbreastcancerprognosisinuswomen
AT antoniouirinim insulinresistancecontributestoracialdisparitiesinbreastcancerprognosisinuswomen
AT leroithderek insulinresistancecontributestoracialdisparitiesinbreastcancerprognosisinuswomen
AT bickellninaa insulinresistancecontributestoracialdisparitiesinbreastcancerprognosisinuswomen